Journal: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Article Title: Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
PMID/MRN: 27798787
Publication Date: 2016-Oct-31
Abstract:
To determine the maximum tolerated dose (MTD) of [ 131 I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [ 131 I]tositumomab has activity against HL and if positron emission tomography (PET) with 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]DG) performed 6Êweeks post-therapy predicted 12-week response.
Separate dose-finding studies were performed for patients with and without prior transplant. A single therapeutic total body radiation dose (TBD) of [ 131 I]tositumomab was administered. TBD was escalated/de-escalated based on dose-limiting hematologic toxicity (DLT) using a modified continual reassessment method. [ 18 F]DG-PET/CT scans were performed at baseline and 6 and 12Êweeks post therapy.
Twelve patients (nine classical HL, three lymphocyte-predominant [LP] HL) completed two dosing levels (nÊ=Ê3 each) in the post-transplant (55ÊcGy, 79ÊcGy) and no transplant (75ÊcGy, 87ÊcGy) groups. Hematologic toxicities were common and transient. Twelve weeks after [ 131 I]tositumomab, 10 patients progressed and two with LPHL achieved complete response. [ 18 F]DG-PET/CT at 6Êweeks post therapy appeared more predictive than CT at 6Êweeks of a response at 12Êweeks.
Tositumomab and [ 131 I]tositumomab was well-tolerated in patients with relapsed/refractory HL. Complete responses in LPHL support a therapeutic effect in this subtype. Early metabolic response assessments by [ 18 F]DG-PET in HL after radioimmunotherapy appear to be more predictive than purely anatomic assessments.